a possible increase in acute pancreatitis risk with gliptins (Januvia, etc) and GLP-1 agonists (Byetta, etc)

April 2013

You'll hear more about a possible increase in acute pancreatitis risk with gliptins (Januvia, etc) and GLP-1 agonists (Byetta, etc).

New evidence suggests about one more case of acute pancreatitis for every 50 diabetes patients using these drugs for up to 2 years.

These incretin mimetics might cause inflammation that could lead to acute pancreatitis...and possibly pancreatic cancer.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote